Endothelins (ETs), 21-amino-acid peptides involved in the pathogenesis of various diseases, bind to ET A and ET B receptors to initiate their effects. Based on the same core structure, we have developed four small-molecule ET receptor antagonists, ABT-627 (atrasentan), ABT-546, A-182086 and A-192621, which exhibit differences in selectivity for ET A and ET B receptors. In this report, we compare the efficacy, potency and pharmacokinetic properties of these four antagonists, including potency in inhibiting ET-1-or Sarafotoxin 6c-induced vessel constriction in isolated arteries and efficacy in antagonizing ET-1-, big ET-1-or Sarafotoxin 6c-induced pressor responses in rats.
INTRODUCTION
the release of nitric oxide [8] , and several lines of evidence support the concept that the ET B receptor is the primary receptor subtype responsible for clearing ET from the circulation [9] .
A major advance was made in the ET field with the development of endothelin receptor antagonists [10] . BQ-123 and FR139317 [11, 12] , two peptidic ET Aselective antagonists, are important tools in the investigation of ET-mediated pathophysiology. Following the peptidic compounds, a number of nonpeptide antagonists with improved pharmacokinetics, such as Ro 47-0203 [13] , SB 217242 [14] , ABT-627 (atrasentan) [15] , etc., were developed. Some of these antagonists are being investigated in human clinical trials [16] .
Recent evidence suggests that ET A receptor may play a more important pathological role than ET B receptor [8] . However, some tissues express ET B receptor predominantly, which seems to suggest that ET B receptor may also play a pathophysiological role [17] . Thus, ET Aselective or ET B -selective antagonists could potentially have their unique utilities. Based on the same chemical structural core, we have developed four nonpeptide ET receptor antagonists, ABT-627, ABT-546, A-182086 and A-192621, which exhibit differences in selectivity for ET A and ET B receptors. The purpose of this report is to compare the potency and pharmacokinetic profiles of these four antagonists utilizing in vivo and ex vivo assay systems.
MATERIALS AND METHODS
ET-1, big ET-1 and sarafotoxin 6c (S6c) were purchased from American Peptide Co. (Santa Clara, CA, U.S.A.). All other reagents were of analytical grade.
Animals
Male Sprague-Dawley rats were purchased from Charles River (Kingston, NY, U.S.A.). New Zealand white rabbits, male, 2.0-2.5 kg, were purchased from Covance (Kalamazoo, MI, U.S.A.). Male and female dogs used in pharmacokinetic studies were purchased from Marshall Research Animals (North Rose, NY, U.S.A.). Female cynomolgus monkeys were obtained from the Abbott Drug Analysis Colony. All protocols utilizing live animals were approved by Abbott Laboratories' Institutional Animal Care and Use Committee and were conducted in AAALAC (American Association for Accreditation of Laboratory Animal Care) accredited facilities.
Vessel contraction
Antagonism of ET-1-or S6c-induced vasoconstriction by test agents was evaluated using isolated rat aortic rings (mediated by ET A ) or rabbit pulmonary artery rings (mediated by ET B ) [18] . The experimental details and the analysis of data by Schild analysis to calculate pA # values have been described previously [19] .
Pharmacokinetics
The pharmacokinetic behaviour of these antagonists was evaluated in male Sprague-Dawley rats (250-300 g), male or female beagle dogs, and female cynomolgus monkeys as described previously [19] .
In vivo pseudoefficacy
The in vivo efficacy of these antagonists was evaluated in male Sprague-Dawley rats (250-350 g) as described previously [19] .
Statistics
Statistical analysis of data was performed using StatView II software (Abacus Concepts, Berkely, CA, U.S.A.). Group comparisons were determined by an ANOVA followed by the Fisher's protected least significant difference test. Unless noted, values are expressed as meanpS.E.M. and n represents the number of animals or separate experiments in each group. Difference test of P 0.05 was considered significant. Figure 1 shows that A-182086 produced concentrationdependent, parallel rightward shifts in the S6c (an ET B receptor-selective receptor agonist) concentrationresponse curve in isolated endothelium-denuded rings of rabbit pulmonary artery (mediated by the vasoconstrictor-type ET B receptor). S6c alone or with A-182086 at increasing concentrations were tested in isolated rabbit pulmonary artery. The Schild analysis of the data is shown as an inset (n l 6 ; a total of 36 pieces of pulmonary artery rings were prepared from six animals). ively. Results for ABT-627 and ABT-546 have been reported previously [15, 18] . The average pA # values of these four compounds are summarized in Table 1 . These data indicate that ABT-627 and ABT-546 are ET Aselective, A-192621 is ET B -selective, while A-182086 is a non-selective antagonist.
RESULTS
The pharmacokinetic profile of A-182086 was examined in rat, dog and monkey. In male SpragueDawley rats, the pharmacokinetic behaviour of A-182086 following a 5 mg\kg intravenous (i.v.) dose was characterized by an apparent plasma elimination half life of 5.0 h. A-182086 was absorbed from the 10 mg\kg oral dose, with peak plasma concentrations recorded 0.5 h after oral (solution) administration. Peak plasma concentrations averaged 2.36 µg\ml, declining with an apparent elimination half life of 8.1 h. The bioavailability of A-182086 was estimated to be 54 % in the rat (Figure 2 ). Similar studies were performed in the beagle dog and in the cynomolgus monkey, and the results are summarized in Table 1 .
The pharmacokinetic studies were repeated for A-192621 in rat, dog and monkey. Results for ABT-627 and ABT-546 have been reported previously [15, 18] . The data from these studies are summarized in Table 1 . These data suggest that these four antagonists exhibit good bioavailability in rat, dog and monkey.
Measurement of big ET-1-and S6c-induced changes in mean systemic arterial blood pressure in conscious, normotensive rats was used to evaluate the in vivo oral efficacy of A-182086 against ET A and ET B receptors respectively.
In Figure 3 , A-182086 (1-100 mg\kg) or vehicle was administered orally by gavage. S6c (0.3 nmol\kg, i.v.) was administered as a bolus 1 h after dosing. The pressor response was quantified by calculation of the area under the curve (AUC MAP ) of mean arterial blood pressure Table 1 . These results indicate that these compounds are efficacious in inhibiting agonist-induced pressor and\or depressor responses as predicted by their selectivity towards the ET A or ET B receptor.
DISCUSSION
We have reported the development and characterization of A-127722 (ABT-627 or atrasentan) and A-216546 (ABT-546), two novel, nonpeptide ET antagonists that are highly selective for ET A , previously [15, 19] . Based on the same core structure, we have developed A-192621 [20] , an ET B -selective antagonist, and A-182086 [21] , a non-selective antagonist. Data clearly demonstrate that these four compounds exhibit distinct characteristics in term of their selectivity towards the two subtypes of ET receptors. ABT-627 and ABT-546 are selective for ET A , while A-192621 is selective for ET B , and A-182086 is a ' balanced ' ET A \ ET B antagonist.
To determine the efficacy of these compounds, we examined the ability of the antagonists to inhibit agonist-induced constriction of vascular tissue utilizing isolated rat aorta and rabbit pulmonary artery. It is known that, in the rat aorta, ET A is the predominant mediator [18] , while in the rabbit pulmonary artery, ET B mediates agonist-induced responses [22] . All four compounds produce a parallel and rightward shift of the agonist (either ET-1 or S6c) concentration-response curve without affecting maximal force, and appear to act as fully competitive receptor antagonists. The potency and selectivity of these four compounds from this study is consistent with that observed in the receptor binding study.
The pharmacokinetic studies indicate that all four compounds are orally available in the rat, dog and monkey. In addition, in the conscious rat, both ABT-627 and ABT-546 exhibit a dose-related inhibition of the blood pressure response to exogenous ET- [23] , suggesting that the ET B receptor is likely to be the clearance receptor for ET-1, and is involved in maintaining arterial blood pressure in the conscious normotensive rat.
In summary, this paper show that four compounds derived from the same core structure are highly potent, orally available ET receptor antagonists with different selectivity toward the two ET receptor subtypes.
